- Charles River Labs reported better-than-expected Q2 2018 results (revenue and earnings), and its management team again raised their full-year guidance.
- The company not only reported impressive operating results for Q2 2018, but it also appears to be well-positioned for the future. Additionally, the company's revenue growth prospects appear promising.
- I plan to stay long the stock, and I may actually add to my position.
Charles River Laboratories ($CRL) has been a top performer for the R.I.P. Portfolio over the first eight months of 2018, as the stock is up almost 14% on a YTD basis.
The outperformance for the stock has been great so far this year, but in my opinion, Charles River's latest quarterly operating results, especially from a revenue standpoint, supports the fact that this Contract Research Organization ("CRO") company is well-positioned for 2018 and beyond.
Read more here.